STAT3 and diabetes mellitus: Thus, miRNAs or novel identified regulatory proteins may serve as potential targets in further clinical developments and represent significant conceptual advances in terms of repression of JAK/STAT3 activation in human diseases, including cancer, diabetes, inflammation, and neurodegenerative disorders.